Virtual reality technology for pain management in advanced cancer
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: Primarily, to determine the effectiveness of a virtual reality (VR) intervention compared to an alternative or no intervention for people living with advanced cancer: on pain intensity, adverse events (AEs) and serious adverse events (SAEs); and secondarily, on additional pain properties (e.g. type, frequency), psychological well-being, other physical symptoms (e.g. anxiety) and quality of life. We will also report on the context in which the VR was implemented (setting, type and dose of VR).
Authors
- Briony F. Hudson (ORCID: https://orcid.org/0000-0002-2907-1764)
- Victoria Vickerstaff (ORCID: https://orcid.org/0000-0002-3119-670X)
- Katie L. Flanagan (ORCID: https://orcid.org/0000-0002-1575-1953)
- Pete Wheatstone (ORCID: https://orcid.org/0000-0003-0869-3449)
- Nicola White (ORCID: https://orcid.org/0000-0002-7438-0072)
- Ollie Minton (ORCID: https://orcid.org/0000-0002-4258-8995)
- Mark Taubert (ORCID: https://orcid.org/0000-0003-0454-5609)
Institutions
- MRC Clinical Trials Unit at UCL (GB)
- Velindre Cancer Centre (GB)
- University Hospitals Sussex NHS Foundation Trust (GB)
- University College London (GB)
- Marie Curie (GB)
Publication Details
- Journal
- Cochrane Database of Systematic Reviews
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1002/14651858.cd016078
- Citations
- 1
- Primary Topic
- Pain Management and Opioid Use
- Type
- article
- Field-Weighted Citation Impact
- 0.64